Cargando…

Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse

BACKGROUND: Weight change during chemotherapy is reported to be associated with a worse prognosis in breast cancer patients, both with weight gain and weight loss. However, most studies were conducted prior to the common use of anthracycline-base chemotherapy and on North American populations with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Thivat, Emilie, Thérondel, Sophie, Lapirot, Olivier, Abrial, Catherine, Gimbergues, Pierre, Gadéa, Emilie, Planchat, Eloïse, Kwiatkowski, Fabrice, Mouret-Reynier, Marie A, Chollet, Philippe, Durando, Xavier
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3006393/
https://www.ncbi.nlm.nih.gov/pubmed/21108799
http://dx.doi.org/10.1186/1471-2407-10-648
_version_ 1782194186340007936
author Thivat, Emilie
Thérondel, Sophie
Lapirot, Olivier
Abrial, Catherine
Gimbergues, Pierre
Gadéa, Emilie
Planchat, Eloïse
Kwiatkowski, Fabrice
Mouret-Reynier, Marie A
Chollet, Philippe
Durando, Xavier
author_facet Thivat, Emilie
Thérondel, Sophie
Lapirot, Olivier
Abrial, Catherine
Gimbergues, Pierre
Gadéa, Emilie
Planchat, Eloïse
Kwiatkowski, Fabrice
Mouret-Reynier, Marie A
Chollet, Philippe
Durando, Xavier
author_sort Thivat, Emilie
collection PubMed
description BACKGROUND: Weight change during chemotherapy is reported to be associated with a worse prognosis in breast cancer patients, both with weight gain and weight loss. However, most studies were conducted prior to the common use of anthracycline-base chemotherapy and on North American populations with a mean BMI classified as overweight. Our study was aimed to evaluate the prognostic value of weight change during anthracycline-based chemotherapy on non metastatic breast cancer (European population) with a long term follow-up. METHODS: Patients included 111 women diagnosed with early stage breast cancer and locally advanced breast cancer who have been treated by anthracycline-based chemotherapy regimen between 1976 and 1989. The relative percent weight variation (WV) between baseline and postchemotherapy treatment was calculated and categorized into either weight change (WV > 5%) or stable (WV < 5%). The median follow-up was 20.4 years [19.4 - 27.6]. Cox proportional hazard models were used to evaluate any potential association of weight change and known prognostic factors with the time to recurrence and overall survival. RESULTS: Baseline BMI was 24.4 kg/m2 [17.1 - 40.5]. During chemotherapy treatment, 31% of patients presented a notable weight variation which was greater than 5% of their initial weight. In multivariate analyses, weight change (> 5%) was positively associated with an increased risk of both recurrence (RR 2.28; 95% CI: 1.29-4.03) and death (RR 2.11; 95% CI: 1.21-3.66). CONCLUSIONS: Our results suggest that weight change during breast-cancer chemotherapy treatment may be related to poorer prognosis with higher reccurence and higher mortality in comparison to women who maintained their weight.
format Text
id pubmed-3006393
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30063932010-12-22 Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse Thivat, Emilie Thérondel, Sophie Lapirot, Olivier Abrial, Catherine Gimbergues, Pierre Gadéa, Emilie Planchat, Eloïse Kwiatkowski, Fabrice Mouret-Reynier, Marie A Chollet, Philippe Durando, Xavier BMC Cancer Research Article BACKGROUND: Weight change during chemotherapy is reported to be associated with a worse prognosis in breast cancer patients, both with weight gain and weight loss. However, most studies were conducted prior to the common use of anthracycline-base chemotherapy and on North American populations with a mean BMI classified as overweight. Our study was aimed to evaluate the prognostic value of weight change during anthracycline-based chemotherapy on non metastatic breast cancer (European population) with a long term follow-up. METHODS: Patients included 111 women diagnosed with early stage breast cancer and locally advanced breast cancer who have been treated by anthracycline-based chemotherapy regimen between 1976 and 1989. The relative percent weight variation (WV) between baseline and postchemotherapy treatment was calculated and categorized into either weight change (WV > 5%) or stable (WV < 5%). The median follow-up was 20.4 years [19.4 - 27.6]. Cox proportional hazard models were used to evaluate any potential association of weight change and known prognostic factors with the time to recurrence and overall survival. RESULTS: Baseline BMI was 24.4 kg/m2 [17.1 - 40.5]. During chemotherapy treatment, 31% of patients presented a notable weight variation which was greater than 5% of their initial weight. In multivariate analyses, weight change (> 5%) was positively associated with an increased risk of both recurrence (RR 2.28; 95% CI: 1.29-4.03) and death (RR 2.11; 95% CI: 1.21-3.66). CONCLUSIONS: Our results suggest that weight change during breast-cancer chemotherapy treatment may be related to poorer prognosis with higher reccurence and higher mortality in comparison to women who maintained their weight. BioMed Central 2010-11-25 /pmc/articles/PMC3006393/ /pubmed/21108799 http://dx.doi.org/10.1186/1471-2407-10-648 Text en Copyright ©2010 Thivat et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Thivat, Emilie
Thérondel, Sophie
Lapirot, Olivier
Abrial, Catherine
Gimbergues, Pierre
Gadéa, Emilie
Planchat, Eloïse
Kwiatkowski, Fabrice
Mouret-Reynier, Marie A
Chollet, Philippe
Durando, Xavier
Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse
title Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse
title_full Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse
title_fullStr Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse
title_full_unstemmed Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse
title_short Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse
title_sort weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3006393/
https://www.ncbi.nlm.nih.gov/pubmed/21108799
http://dx.doi.org/10.1186/1471-2407-10-648
work_keys_str_mv AT thivatemilie weightchangeduringchemotherapychangestheprognosisinnonmetastaticbreastcancerfortheworse
AT therondelsophie weightchangeduringchemotherapychangestheprognosisinnonmetastaticbreastcancerfortheworse
AT lapirotolivier weightchangeduringchemotherapychangestheprognosisinnonmetastaticbreastcancerfortheworse
AT abrialcatherine weightchangeduringchemotherapychangestheprognosisinnonmetastaticbreastcancerfortheworse
AT gimberguespierre weightchangeduringchemotherapychangestheprognosisinnonmetastaticbreastcancerfortheworse
AT gadeaemilie weightchangeduringchemotherapychangestheprognosisinnonmetastaticbreastcancerfortheworse
AT planchateloise weightchangeduringchemotherapychangestheprognosisinnonmetastaticbreastcancerfortheworse
AT kwiatkowskifabrice weightchangeduringchemotherapychangestheprognosisinnonmetastaticbreastcancerfortheworse
AT mouretreyniermariea weightchangeduringchemotherapychangestheprognosisinnonmetastaticbreastcancerfortheworse
AT cholletphilippe weightchangeduringchemotherapychangestheprognosisinnonmetastaticbreastcancerfortheworse
AT durandoxavier weightchangeduringchemotherapychangestheprognosisinnonmetastaticbreastcancerfortheworse